Tranexamic acid reduces blood loss in patients wit fractures of the hip: a randomized control trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015809

Enrollment

Unknown

Registered

2018-04-22

Start date

2018-05-01

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fracture of hip

Interventions

A:IV TXA

B:oral TXA 2G

C:topical TXA

D:various doses oral TXA

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. THA for hip fracture; 2. Patinets with preoperative platelet and coagulation function dysfunction; 3. Preoperative double lower limb venous color Doppler ultrasound was not abnormal; 4. voluntarily participated in clinical trials and signed informed consent, good compliance of patients.

Exclusion criteria

Exclusion criteria: 1. Patient with history of venous thromboembolism, pulmonary embolism, cerebral infarction, coronary heart disease; 2. Patients with coagulation disorders; 3. Anticoagulant drugs are being used; 4. Administration of NSAID for less than 1 weeks; 5. TXA allergy; 6. Severe liver and renal insufficiency; 7. Patients with high risk of thrombosis, including atrial fibrillation, cardiac pacemaker, and stent implantation.

Design outcomes

Primary

Measure	Time frame
Blood measurement;function;inflammation marker;Anticoagulation marker;Fibrinolysis marker;	—

Countries

China

Contacts

Public ContactZhou Zongke

West China Hospital, Sichuan University

zongke@126.com+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026